- Home
- MUA vs LRMR Comparison
MUA vs LRMR Comparison
Compare MUA & LRMR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MUA | LRMR |
|---|---|---|
| Founded | N/A | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Bankers/Brokers/Service | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 517.6M | 455.8M |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | MUA | LRMR |
|---|---|---|
| Price | $10.25 | $4.16 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $16.50 |
| AVG Volume (30 Days) | 225.8K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $1,816.14 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $2.72 |
| 52 Week High | $11.78 | $6.42 |
Technical Indicators
Market Signals| Indicator | MUA | LRMR |
|---|---|---|
| Relative Strength Index (RSI) | 29.46 | 61.95 |
| Support Level | $10.17 | $3.01 |
| Resistance Level | $10.87 | $4.21 |
| Average True Range (ATR) | 0.10 | 0.23 |
| MACD | -0.04 | 0.03 |
| Stochastic Oscillator | 18.57 | 84.51 |
Price Performance
Historical ComparisonAbout MUA Blackrock MuniAssets Fund Inc
Blackrock Muniassets Fund Inc is a closed-end fund. Its objective is to provide high current income exempt from U.S. federal income taxes by investing in a portfolio of medium- to lower-grade or unrated municipal obligations. The Fund invests more of its total assets in municipal bonds.
About LRMR Larimar Therapeutics Inc.
Larimar Therapeutics Inc is a clinical-stage biotechnology company focused on developing treatments for patients suffering from complex rare diseases using its novel cell-penetrating peptide (CPP) technology platform. Its lead product candidate, CTI-1601, is a subcutaneously administered, recombinant fusion protein intended to deliver human frataxin (FXN) an essential protein, to the mitochondria of patients with Friedreich's ataxia.